Lilly Cancer Treatment Falls Short in Study

Posted: Updated:
(Image Courtesy: Lilly Oncology) (Image Courtesy: Lilly Oncology)
INDIANAPOLIS -

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced it will not seek regulatory approval on another use for one of the key treatments in its cancer portfolio. In a late-stage study, CYRAMZA met its main goal of progression free-survival in patients with certain types of gastric or gastroesophageal cancer, but did not improve a secondary endpoint: overall survival rate.

Lilly Oncology Senior Vice President of Global Development and Medical Affairs Levi Garraway said "while we hoped that the positive PFS outcome would have translated into an OS benefit, these RAINFALL results highlight the challenges associated with improving outcomes for people with advanced gastric cancer. This is underscored by the fact that there have been no major advances over standard chemotherapy in the first-line HER2-negative gastric cancer treatment setting in the last decade. Lilly is deeply committed to patients with this aggressive disease, and CYRAMZA remains a standard of care in the second-line treatment paradigm for advanced gastric cancer patients around the world. We thank the patients, their caregivers and investigators for their support of and participation in the RAINFALL study."

CYRAMZA is currently combined with other medications or used alone in treatment of several illnesses including metastatic non-small cell lung cancer, advanced gastric cancer, gastroesophageal junction cancer and metastatic colorectal cancer.

You can connect to more about the results and CYRAMZA by clicking here.

  • Perspectives

    • Culp worries that newly-elected officials will "absorb the message that TIF is bad."

      Top Five Out-of-Site Trends in Site Selection

      Whenever anyone asks me about my job, their first question is usually "what are the big trends in your industry?" Just kidding. Their first question is "you do what now?" But once we get past that they want to know what factors are driving our clients' decisions.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Purdue Fort Wayne Unveils New Sports Branding

      Purdue University Fort Wayne has unveiled a new look for its sports teams. The university says it will continue to use the Mastodon as its mascot, however a new logo and color scheme will be used to better match with the Purdue brand.

    • Delta Begins Nonstop to Seattle

      Delta Air Lines now offers a nonstop flight from Indianapolis International to Seattle-Tacoma International Airport. The first flight leaving Monday night will be a milestone for the Indy airport, since it will now connect to all Delta hubs in the U.S. 

    • Culp worries that newly-elected officials will "absorb the message that TIF is bad."

      Top Five Out-of-Site Trends in Site Selection

      Whenever anyone asks me about my job, their first question is usually "what are the big trends in your industry?" Just kidding. Their first question is "you do what now?" But once we get past that they want to know what factors are driving our clients' decisions.

    • Ohio River Crossing Updates Prove More Costly

      The I-69 Ohio River Crossing Project Team has unveiled updated preliminary alternatives for I-69 bridge and interstate connections that come with higher price tags. The group says the changes on the Evansville-to-Henderson, Kentucky project were based in part on public input on factors ranging from routes to tolling.

    • Ball Brothers Foundation Awards Millions in Grants

      Over 30 organizations have been awarded more than $3.2 million in the first round of 2018 grants for the Ball Brothers Foundation. The foundation has awarded no less than $6.3 million per year to various organizations since 2013. T